Research note
Sartorius shows demand recovery with stronger cash conversion
Sartorius reported 8.1% constant-currency operational sales growth excluding U.S. tariff compensation for the first nine months of 2026, alongside a 55.2% increase in free cash flow.
Evidence snapshot
What the evidence says
Short answer: Sartorius reported 8.1% constant-currency operational sales growth excluding U.S. tariff compensation for the first nine months of 2026, alongside a 55.2% increase in free cash flow.
- Research as of
- 2026-10-26
- Confidence
- Medium
- Primary sources
- 1
Use the dated primary-source trail below for time-sensitive claims. Reported evidence and public interpretation are kept separate.
Change record
What changed
- Recurring consumables remained a growth driver while bioprocess equipment and instrument demand continued to recover.
- Underlying EBITDA margin rose 0.5 percentage points to 30.2%; operating cash flow increased 9.9% and free cash flow reached €310 million as investment declined.
Public interpretation
Why it matters
The combination of demand recovery, margin and cash is stronger conversion evidence than a product-capability page. It still does not isolate qualified bioprocess throughput or AI-specific revenue.
Primary-source trail
Evidence
- Sartorius: nine-month 2026 results
Operational sales growth, margin, cash flow, investment and demand commentary. · As of 2026-10-22